Plasma exosome miR-155-5p as an independent prognostic risk factor for Mycosis Fungoides

Adam Cohen-Nowak  
*Thomas Jefferson University, adam.cohen-nowak@jefferson.edu*

Neda Nikbakht  
*Thomas Jefferson University, neda.nikbakht@jefferson.edu*

Follow this and additional works at: [https://jdc.jefferson.edu/si_ctr_2022_phase1](https://jdc.jefferson.edu/si_ctr_2022_phase1)

Part of the Dermatology Commons, and the Translational Medical Research Commons

Let us know how access to this document benefits you

**Recommended Citation**

[https://jdc.jefferson.edu/si_ctr_2022_phase1/84](https://jdc.jefferson.edu/si_ctr_2022_phase1/84)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Introduction: Mycosis Fungoides (MF) is a rare non-Hodgkin Lymphoma with variable progression that comprises half of all cutaneous T-cell lymphomas (CTCLs). Previous studies have shown higher expression of the micro-RNA miR-155-5p isolated from biopsies of MF tumors compared to early-stage lesions and healthy skin, illustrating the potential for miR-155-5p to serve as a prognostic indicator. Small extracellular vesicles (30-150 nm) called exosomes are known to play a role in cancer signaling and progression by carrying micro-RNAs. However, no studies have measured circulating exosomal miR-155-5p in the blood of patients with MF. We hypothesize that miR-155-5p is expressed higher in plasma exosomes of patients with MF compared to healthy volunteers.

Methods: 6 patients with a diagnosis of MF and 9 healthy patients at Jefferson Dermatology Associates were enrolled in the study. Phlebotomy samples were obtained and plasma isolated by centrifugation. Exosomes were extracted by ExoQuick reagent and size confirmed by NanoSight software. RNA was extracted and qRT-PCR performed with Taqman probes for miR-155-5p and miR-103 (control). Delta-delta CT analysis was performed to analyze expression.
**Results:** Analysis of three PCR runs determined the control (miR-103) to be expressed differently across samples with poor amplification. Additionally, miR-155-5p was variably expressed in the samples extracted from healthy volunteers. No pattern is discernible.

**Discussion:** Given that sample volume is a proxy for pre-reaction cDNA in each sample, adaptation of the protocol and a new control is needed to more accurately measure miRNA expression. No conclusions can be made at this time.